For a U.S. citizen, the rule says no, with a narrow exception that is left to officers’ discretion. FDA’s personal importation page says that “in most circumstances, it is illegal for individuals to import drugs or devices into the U.S. for personal use,” and that a drug approved in another country but unapproved here “is illegal to import”[1].
That reaches a pen of Ozempic or Wegovy bought at a pharmacy in Tijuana or Toronto, even when the box carries the same brand name as the semaglutide pen sold at home. U.S. prices for the brand pens are in Ozempic cost and Wegovy cost.
Why a brand-name pen still counts as unapproved
CBP spells this out on its page for travelers. It says a U.S. citizen should travel only with medication prescribed by a licensed physician “and/or legally obtained in the United States,” and that in most cases it is illegal to obtain drugs abroad and import them for personal use[2].
The reason it gives is the one that matters for GLP-1s. Drugs available in other countries, “including foreign-made versions of drugs approved for use in the U.S.,” have not been evaluated or approved by FDA for use or sale here, so FDA “generally considers such drugs unapproved”[2]. The U.S. approval covers the product made and labeled for the U.S. market, not every box that shares its name.
Where the discretion comes in
Both pages point to section 9-2 of FDA’s Regulatory Procedures Manual, the internal guide its staff work from[1][2]. It lets FDA personnel “allow entry of shipments when the quantity and purpose are clearly for personal use, and the product does not present an unreasonable risk to the user”[3]. The next sentences close the door again: violative products stay subject to refusal, and the discretion “should not be interpreted as a license to individuals to bring in such shipments”[3].
| Situation | What the manual requires |
|---|---|
| Not for a serious condition | The intended use is appropriately identified, it is not for treatment of a serious condition, and the product is not known to represent a significant health risk |
| For a serious condition | Effective treatment may not be available domestically; no known commercialization or promotion to U.S. residents; no unreasonable risk; a written statement that it is for the patient's own use (generally no more than a three-month supply); and either a U.S.-licensed doctor's name and address or evidence of treatment begun abroad |
The second situation is the one people usually picture, and its first condition is the hard one for a GLP-1. It is written for a treatment that “may not be available domestically either through commercial or clinical means”[3]. A drug with a U.S.-approved version on pharmacy shelves here is not the case that condition describes.
The manual also gives officers a way to spot a shipment that is not personal. Among the factors, FDA staff may consider whether “the supply exceeds what one person might take in approximately three months,” and commercial shipments fall outside these procedures altogether[3]. A suitcase of pens bought for friends is the shape that test is built to catch.
In your bag or in the mail
At a land crossing or an airport, FDA staff do not search your bag. The manual says FDA personnel “are not to examine personal baggage,” which is CBP’s job. A CBP officer is expected to call FDA in when a product looks commercial, has been flagged for detention, or appears to be a health fraud or an unknown risk to health[3].
Ordering from a foreign pharmacy website is treated differently. Parcels arriving through the international mail facilities are examined by CBP's mail division, which sets aside anything that appears to contain a drug, and FDA then decides whether to release, detain or refuse it.[3] A refused drug valued at $2,500 or less, or one that fails the personal importation criteria, is destroyed by FDA rather than sent back[3]. The notice, the response window and the destruction step are set out in notice of FDA action.
Cold storage is the other problem with carrying a pen home, whatever its origin. Time out of the refrigerator is set by the label on the product, and the general rules are in can you fly with peptides.
Canada is not an exception
Neither the FDA page nor the CBP page names a country that is treated more gently[1][2]. A pen dispensed by a Canadian pharmacy is a foreign-made version in the same sense as one from Mexico, and the same rule and the same discretion apply.
Visitors are the one group with a stated allowance
The rules above are written for U.S. citizens. FDA handles foreign nationals separately. Someone who is not a citizen or permanent resident, visiting for vacation, study or work, may bring or ship a 90-day supply of their medication. If the stay runs longer, more may be sent by mail[1]. CBP adds that visitors should carry a valid prescription or doctor’s note in English, with the medication in its original container[2].
That allowance is for a person who lives abroad bringing their own treatment in. It is not a route for a U.S. resident to stock up on a trip.
What this means for the price you compare
The saving people cross the border for is measured against a U.S. price. The legal routes for that comparison are the brand pens as sold by U.S. pharmacies, and state-licensed pharmacies for compounded tirzepatide and semaglutide. The compounded side is priced in compounded semaglutide cost, and the wider comparison is in GLP-1 cost without insurance.
The one question to ask before you buy abroad: “Is this product approved for the U.S. market, or is it a foreign-made version that FDA treats as unapproved?”